Bladder Cancer Coverage from Every Angle

Petros Grivas, MD, PhD, on Urothelial Carcinoma Roundup: Expert Perspective

Posted: Wednesday, September 20, 2017

Petros Grivas, MD, PhD, of the Cleveland Clinic’s Taussig Cancer Institute, summarizes a session he chaired on urothelial cancer, with papers covering tumor mutation burden; nivolumab efficacy; and epithelial-mesenchymal transition, T-cell infiltration, and outcomes with nivolumab in this disease setting.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.